MedTrace Logo

Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients

NCT05944458 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-07-14

No results posted yet for this study

Summary

* Study the effect of acetylcysteine on decreasing the incidence of LIT in critically ill patients.
* Study the impact of acetylcysteine on the time to onset of LIT and the time to recovery of platelets.

Conditions

Interventions

DRUG

N acetyl cysteine

Fluimucil 600 mg iv to be taken twice daily as infusion

DRUG

Placebo

20 ml normal saline iv every 12 hours

Sponsors & Collaborators

  • Helwan University

    lead OTHER

Principal Investigators

  • Mohamed Abdeltawab, Pharm D · Clinical pharmacy, 15 May hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05944458 on ClinicalTrials.gov